Sven Zukunft

23PUBLICATIONS
129CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Epidemiological methodsCellular immunologyEpidemiological modellingGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Mar 03, 2026
Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer.

Meggy Suarez-Carmona, Mareike Hampel, Xin-Wen Zhang

|Oct 02, 2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

Katja Sockel, Christoph Röllig, Anke Mütherig

|Jul 21, 2025
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Julian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch

|Nov 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

Christian Récher, Pierre-Yves Dumas, Emilie Bérard

|Nov 06, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia.

Leo Ruhnke, Marius Bill, Sven Zukunft

|Sep 18, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.

Julia M Unglaub, Richard F Schlenk, Jan Moritz Middeke

Pageof 4

Frequent Collaborators

8 joint publications

Ingrid Fleming

5 joint publications

Stephan Klatt

5 joint publications

Andreas Weigert

4 joint publications

Stefan W Krause